ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE CONSERVATIVE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1
Amin, A., Essa, H., Hamed, D., Sheha, H., Morsy, A. (2023). ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE CONSERVATIVE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1. EKB Journal Management System, 46(1), 281-290. doi: 10.21608/bfsa.2023.300947
A. F. Amin; H. H. Essa; D. A. Hamed; Heba Sheha; A. M. Morsy. "ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE CONSERVATIVE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1". EKB Journal Management System, 46, 1, 2023, 281-290. doi: 10.21608/bfsa.2023.300947
Amin, A., Essa, H., Hamed, D., Sheha, H., Morsy, A. (2023). 'ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE CONSERVATIVE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1', EKB Journal Management System, 46(1), pp. 281-290. doi: 10.21608/bfsa.2023.300947
Amin, A., Essa, H., Hamed, D., Sheha, H., Morsy, A. ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE CONSERVATIVE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1. EKB Journal Management System, 2023; 46(1): 281-290. doi: 10.21608/bfsa.2023.300947

ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE CONSERVATIVE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1

Bulletin of Pharmaceutical Sciences Assiut University
Volume 46, Issue 1, June 2023, Page 281-290  XML PDF (921.5 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2023.300947
View on SCiNiTO View on SCiNiTO
Authors
A. F. Amin1; H. H. Essa1; D. A. Hamed2; Heba Sheha email 3; A. M. Morsy1
1Department Clinical Ocology, Assiut University Hospital, Assiut, Egypt
2Department Urology, Assiut University Hospital, Assiut, Egypt
3Assiut University hospital
Abstract
Aim:In this study our aim is to evaluate the benefit of neoadjuvant chemotherapy (NAC) in high risk NMIBC in preventing disease recurrence and progression while improving overall survival (OS).Patients and Methods:This prospective study included 33 patients with a pathologically confirmed NMIBC(T1) at the time of Transurethral resection of a bladder tumor (TURBT) with one or more high risk features (HRFs) during the period (2019- 2022),at Assiut University Hospital. All patients received 3 cycles neoadjuvant chemotherapy (cisplatin-gemcitabine) every 3 weeks and assessment of response was done by pelviabdomen Multi slice-CT and cystoscopy then TURBT and kept under follow up every 3 months by cystoscopy in the first 2 years. Results: A complete response (CR) was observed in 82% of the patients and disease progression (DP) to in 18% of the patients. Two year OS rate was 79% and two year disease free rate survival(DFS) was 76%.In Univariate regression t Patients with one risk features were 7 time more in 2 years DFS than patients with ≥ 2 risk features (OR= 6.90), Patients with no foci of squamous differentiation were 5 time more in 2 years DFS than patients with foci of squamous differentiation (OR= 5.25) and all factors were significant. In a multivariate regression model the significant variable only was Patients with no foci of squamous differentiation(OR= 6.92).Conclusion:NAC seems to have promising results in treatment of patients with one HRF NMIBC and a further investigation needed to determine the role of multimodal therapy in patients with two or more high risk feature NMIBC
Keywords
Neoadjuvant chemotherapy; Non Muscle Invasive Bladder Cancer; Transurethral resection of a bladder tumor; Overall Survival; Disease Free Survival
Statistics
Article View: 170
PDF Download: 151